Related Experiment Videos
Sequential studies of complement activation in systemic lupus erythematosus
Insights
Systemic lupus erythematosus (SLE) flares are linked to complement system activation, specifically C1 activation preceding flares and C3d indicating severe disease. Monitoring these markers aids in predicting and managing SLE exacerbations.
Area of Science:
- Immunology
- Rheumatology
- Complement System Biology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by unpredictable flares.
- The complement system, particularly C1 and C3, plays a crucial role in SLE pathogenesis.
- Understanding complement activation patterns can provide insights into disease activity and progression.
Purpose of the Study:
- To investigate the role of C1 and C3 activation in SLE exacerbations.
- To determine if complement activation markers can predict disease flares.
- To correlate complement activation with disease severity and clinical manifestations.
Main Methods:
- Serial serum samples from 33 SLE patients with documented exacerbations were analyzed.
- C1 activation was measured via C1r-C1s-C1 inactivator (C1-IA) complexes.
- Circulating C3d levels and C1q-based immune complexes were quantified.
Main Results:
- Increased C1 activation correlated with SLE exacerbations.
- Elevated C3d levels were associated with severe disease flares.
- C1 activation preceded flares, particularly in extra-renal SLE, while C3d indicated severe flares.
- Decreasing C1-IA and C3d levels paralleled clinical remission.
Conclusions:
- C1 activation is a consistent marker of SLE exacerbation and can precede flares, especially in extra-renal disease.
- Circulating C3d is indicative of severe SLE flares and potential renal complications.
- Complement activation patterns offer valuable insights for monitoring SLE activity and guiding treatment.
Abstract:
C1 and C3 activation, measured as C1r-C1s-C1 inactivator C1s-C1r-C1IA complexes in serum and circulating C3d were studied in serial samples from 33 patients with SLE. All patients demonstrated exacerbations during observation periods of 10-30 months and were divided into groups according to principal clincal features (mild SLE, severe extra-renal SLE, and lupus glomerulonephritis). Increased C1 activation was consistently found during exacerbation. C3d in plasma was a feature associated with severe disease flares. Activation of C1, but not of C3, was documented before flare-ups of disease activity, but such predictive information was mostly restricted to patients with extra-renal disease. C2 cleavage in plasma, studied serially in a few patients, appeared to be closely associated with C1 activation. Circulating immune complexes, measured with solid-phase C1q assay, did not always increase before development of clinical manifestations. Remission of symptoms was paralleled by decreasing concentrations of C1r-C1s-C1IA and of, when present, C3d. Similar findings were made for immune complexes but only in severe disease. Persisting C3d was observed in 3 patients, who subsequently developed renal failure. C1q levels were transiently low during flare-ups of lupus glomerulonephritis, but otherwise the concentrations of C1q, C4 and C3 did not show consistent patterns of variation in relation to disease activity.